CD274 and familial pancreatic carcinoma: In this global trend, immunotherapy was also expected to be effective in pancreatic cancer, but the efficacy of immune checkpoint inhibitors (for example, anti-CTLA-4 antibodies and anti-PD1/PD-L1 antibodies) currently in clinical use is limited.